All posts by imreal

Gabrielle Clemens Publishes New Book “Marriage is About Love Divorce Is About Money® – The Business of Divorce”


Gabrielle Clemens, CDFA®, JD, LLM, AEP®

“I wrote this book to educate people as they contemplate, navigate, and recover from the divorce process. There are so many questions and decisions that people are being asked to make throughout the divorce process, at a time when people are emotional and facing uncertainly,” said Clemens

Gabrielle Clemens, Certified Divorce Financial Analyst (CDFA®), JD, LLM, Accredited Estate Planner (AEP®), is excited to announce that she has published a book entitled, “Marriage is About Love Divorce Is About Money®” – the first in The Business of Divorce® series with more to come.

The book is a step-by-step guide through the legal and financial aspects of divorce from an attorney and certified divorce financial advisor’s perspective and provides guidance on developing an action plan and comprehensive strategy for anyone who is contemplating, navigating, or recovering from the divorce process. Topics include: How to navigate the legal process, how to understand and document finances, and how to build an emotional support system.

“I wrote this book to educate people as they contemplate, navigate, and recover from the divorce process. There are so many questions and decisions that people are being asked to make throughout the divorce process, at a time when people are emotional and facing uncertainly. My goal is to provide insight and a guide to the divorce process so that people can make informed, sustainable decisions about their future,” said Clemens.

Gabrielle joined the financial services industry after working several years as both a divorce and trust and estate planning attorney with an emphasis on tax. She earned a graduate law degree in taxation (LLM) from Boston University School of Law and a Juris Doctor (J.D.) degree from the University of New Hampshire School of Law. She scribes a monthly Ask Gabrielle column in Boston Common Magazine and has been recognized with several prestigious awards, including being named a Forbes Top Women Wealth Advisor Best in State, a Forbes Best-In-State Wealth Advisor, a Working Mother’s Top Wealth Advisor, and Advisor Hub – #1 Advisors to Watch.

Although she has a broad-based clientele, Gabrielle primarily works with high-net-worth and divorced or divorcing individuals and couples. She offers divorce financial planning seminars and workshops throughout New England, is a frequent guest on local and national media outlets, and does many public speaking engagements.

A link to more info can be found here.

Gabrielle can be reached at gabrielle.clemens@gmail.com.

Share article on social media or email:

Climate change likely to turn New York into a breeding ground for dengue-carrying mosquitoes


News Image

Greater awareness of this risk and earlier interventions are critical in mitigating against spread.

BlueDot Inc., a leading artificial and human intelligence organization for detecting, assessing, and responding to global infectious disease threats, announced today that its latest forecasting models reveal that climate change is causing a major expansion of areas where Aedes (Ae.) genus mosquitoes could breed and survive over the next 10 years. These mosquitoes are known carriers for chikungunya, dengue, yellow fever and Zika, which are four of the most disruptive mosquito-borne diseases.

BlueDot data scientists have found that the Ae. albopictus and Ae. aegypti mosquitoes have the potential to expand upwards of 400 kilometers into the north, reaching major cities like Beijing, London, New York, and Toronto – potentially exposing over 40 million people* in these cities alone. Driven by factors like climate change, urbanization, and ecosystem disruption, mosquitoes have already begun to move beyond their traditional habitat and have been found in some of these regions**.

BlueDot had previously predicted the first outbreak of Zika virus in Florida, U.S. six months before it occurred. It also alerted its clients of COVID-19 nearly a week before the World Health Organization, and correctly identified many of the first international cities in which it would first emerge. To address the increasing frequency and severity of infectious diseases, BlueDot has brought in new data and scientific methods which allow for powerful analysis on changing seasonal disease spread.

“Greater awareness of this risk and earlier interventions are critical in mitigating against spread”, stated Dr. Andrea Thomas, Director of Epidemiology. “We’ve never before seen mosquitoes appear within these territories, at a rate where local infection is possible.”

BlueDot utilizes a gradient-boosted regression tree model to forecast global climatic suitability for Ae. albopictus and Ae. aegypti mosquitoes under the projected climate over the next 10 years with five-by-five-kilometre granularity. Precipitation, surface temperature, and elevation are used, along with historical mosquito occurrence data, to fit the models. They also evaluate three different climate scenarios which look at best-case, most-likely, and worse-case changes.

The results underline the need for education on mosquito-borne diseases, and procurement of medical and safety countermeasures such as insect repellant, removal of standing water, appropriate clothing or netting, and vaccinations (where applicable).

Further information on how the analysis was conducted can be found here (https://bluedot.global/anticipating-burden-of-disease-mosquito-borne-illness/) or via webinar here (https://bluedot.global/how-to-assess-burden-of-disease-na/).

*Sources: Based the combined estimated populations for Beijing, London, Toronto, and New York City

**Source: Windsor-Essex Health Unit

About BlueDot 

BlueDot’s intelligence platform empowers public and private sector organizations to rapidly identify, understand, and effectively respond to global biothreats. Combining human and artificial intelligence to track hundreds of infectious diseases and syndromes worldwide, it applies academic data science expertise to anticipate global spread and impact. BlueDot ensures clients know first when disease events emerge, are prepared to respond, can focus on what matters, and can act swiftly and confidently when needed. Founded in 2013 and used by the City of Chicago, Taiwan CDC, Air Canada and more, BlueDot helps clients make critical decisions with clarity and confidence. Learn more at http://www.bluedot.global.

Share article on social media or email:

CellMax Life Announces Expansion of GI Medical Advisory Board


CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the expansion of its medical advisory board. The board is comprised of highly respected and experienced leaders in colorectal cancer screening and prevention.

The company welcomed four new members to its existing board, which consisted previously of Shai Friedland, MD, a gastroenterologist at Stanford Medicine, Ashish Nimgaonkar, MD, a gastroenterologist at Johns Hopkins Medicine, and Samir Gupta, MD, a gastroenterologist at UC San Diego Health, who will all continue to serve on the board.

The new board members include: Douglas Rex, MD, a gastroenterologist at Indiana University Health; Aasma Shaukat, MD, a gastroenterologist at NYU Langone Health; Brooks Cash, MD, a gastroenterologist at UTHealth Houston; and Jack Di Palma, MD, a gastroenterologist at USA Health.

“It is my honor to welcome these industry leaders who bring significant depth of expertise in the field of colorectal cancer, especially as it relates to prevention and screening; they will bring significant value as we build and launch our premarket approval study,” said Atul Sharan, CEO of CellMax Life. “With their guidance we are confident that FirstSight will play a crucial role in increasing screening adherence and reduce mortality with its ability to detect precancerous adenomas.”

Each new board member brings an impressive background.


  • Douglas Rex, MD, is a distinguished professor emeritus of medicine at Indiana University School of Medicine. Previously, he served on the U.S. Multi-Society (ACG, ASGE, AGA) Task Force on Colorectal Cancer and as president of the American Society for Gastrointestinal Endoscopy (ASGE). Dr. Rex co-authored the colorectal cancer screening recommendations of the American College of Gastroenterology and the U.S. Multi-Society Task Force on Colorectal Cancer. He has authored more than 330 original research papers, 60 book chapters, 60 editorials, and 40 guideline papers.
  • Aasma Shaukat, MD, is a professor of medicine with the Department of Medicine at NYU Grossman School of Medicine and a professor with the Department of Population Health at NYU Grossman School of Medicine. She is the first author of the newly updated “ACG Clinical Guidelines: Colorectal Cancer Screening 2021” and is highly regarded as a thought leader in the space, publishing over 160 peer-reviewed articles in numerous top-tier medical publications
  • Brooks Cash, MD, is chief of the division of gastroenterology, hepatology, and nutrition at the University of Texas Health Science Center at Houston. He also serves as a professor of medicine at the University of Texas McGovern Medical School and is a Senior Associate Editor for the American Journal of Gastroenterology. A recognized expert in evidence-based clinical care, Dr. Cash has conducted pioneering research in emerging testing options for colorectal cancer screening, has authored more than 250 original research papers, review articles, and guidelines in prestigious medical journals, and has served as editor and contributor to 15 gastroenterology focused textbooks.
  • Jack Di Palma, MD, is program director of the division of gastroenterology at University of South Alabama Health and the director of section of inflammatory bowel diseases at University of South Alabama Health. Dr. Di Palma also works as a professor of internal medicine and digestive health at University of South Alabama Health and previously served as President of the American College of Gastroenterology (ACG).

“I am excited to join CellMax’s medical advisory board and to be with this highly accomplished group that brings significant experience in gastroenterology, and in particular, colorectal cancer screening and prevention,” said Dr. Rex. “In order to significantly reduce mortality associated with colorectal cancer, a blood-test that can detect both CRC & AAs with high sensitivity is needed. This is why I am enthusiastic about FirstSight.”

About CellMax Life:

CellMax Life is a diagnostics company focused on cancer screening with proprietary technology for detecting precancerous and cancer cells and genomic aberrations in a single blood sample. CellMax Life is headquartered in Sunnyvale, California, and has an accredited laboratory at this location. For more information, visit http://www.cellmaxlife.com.

Disclosure:

As Principal Investigator for CellMax clinical studies Dr. Shai Friedland’s position as a medical advisory board member is not compensated.

Media Contact:

Leonard Fontes III

cellmaxlife@antennagroup.com

(551)-287-2970

Share article on social media or email:

Texere Publishing Fortifies US Presence with C&EN’s Former Vice President and Editor in Chief


Texere Publishing Appoints Bibiana Campos-Seijo as Strategic Advisor

Bibiana Campos-Seijo: “Texere has become what a lot of media companies aspire to be: nimble, innovative, and disruptive… and I’m excited to join their ranks and help further accelerate their expansion in new and existing markets.”

Texere Publishing Inc is delighted to announce that Bibiana (“Bibi”) Campos Seijo has accepted a position as Strategic Advisor.

The recipient of the 2021 G. D. Crain Jr. Leadership award in recognition of “outstanding contributions to the development of editorial excellence in business media,” Bibi has held a string of high-profile positions.

Bibi spent the last eight years at the American Chemical Society, Washington, D.C., as Vice President of C&EN Media and Group, and Editor in Chief of C&EN, leading a team of around 50 staff across editorial, audience, creative, product, and operations functions. There, among many other achievements, Bibi established an awards program (C&EN’s Talented 12), an annual event (C&EN Futures Festival), and an award-winning custom content unit (C&EN BrandLab).

Before that, Bibi spent over six years at the Royal Society of Chemistry, Cambridge, UK, as Editor in Chief, Chemistry World, and Publisher, Magazines.

Speaking of the appointment, Andy Davies, CEO of Texere, said, “Texere is and always will be committed to attracting the very best talent – it is a cornerstone of our success. Bibi is a perfect example of this approach. Bringing a wealth of proven experience not only in content delivery but also in forming strong networks and partnerships, Bibi will play an important strategic role in our continued expansion into the North American market and beyond.”

Content Director Rich Whitworth added, “I’ve had the pleasure of crossing paths with Bibi at several events over the last 10 years – and, in between times, I’ve simply admired her work from afar. I am very much looking forward to collaborating closely with Bibi on a number of exciting projects – the details of which I am sure we’ll reveal as the year and partnership progresses!”

Bibi commented, “Texere has become what a lot of media companies aspire to be: nimble, innovative, and disruptive. I’ve been very impressed with the pace of growth that Texere has seen in its first decade – and I’m excited to join their ranks and help further accelerate their expansion in new and existing markets.”

ENDS

About Texere Publishing

At Texere Publishing, we deliver compelling, behind the scenes stories that matter in the life sciences and medicine. Our unrivaled access to key opinion leaders, influencers, scientists, and doctors who are making a difference, allows us to connect our readers to the pulse of their fields. Founded in 2012, we have expanded our editorial beat around the world with a physical presence in the US, Canada, and the UK. Visionary. Innovative. Fearless. Join us on our journey to cover the stories that matter to you.

Publishers of The Analytical Scientist, The Cannabis Scientist, The Medicine Maker, The Ophthalmologist, The New Optometrist, The Pathologist, The Translational Scientist and ID Transmission.

texerepublishing.com | Twitter | LinkedIn | Instagram | Facebook

MEDIA CONTACTS:

Katy Pearson | Marketing Manager

+44 (0) 1565 745 200 | katy.pearson@texerepublishing.com

Share article on social media or email:



Baptist Memorial Health Care Enters Into an Agreement with LookDeep to Expand Inpatient Telehealth Capabilities


“We are thrilled to collaborate with Baptist Memorial Health Care, as their deep experience and innovation with telemedicine in urban and rural hospitals is the perfect setting for our AI technology to prove its worth,” said Narinder Singh, CEO and Co-Founder of LookDeep

Baptist Memorial Health Care and LookDeep Health today announced a collaboration to expand inpatient telehealth capabilities at Baptist Memorial Health Care.

LookDeep’s Clinical Action Platform, built on modern SOC2 Type II audited software, enables health systems to securely tackle inpatient telemedicine needs with a single solution. Its powerful computer vision and AI capabilities aid sitters, nurses, therapists, and doctors in continuously monitoring patients at every moment of their hospital journey.

“We are excited about our collaboration with LookDeep to use AI to expand virtual safety, nursing and medical services to support our staff and improve patient care,” said Dr. Paul DePriest, Executive Vice President and Chief Operating Officer for Baptist Memorial Health Care. “We evaluated the solution at one of our hospitals and believe it could be valuable to advancing the telemedicine program throughout our health care system.

”LookDeep’s advanced AI technology continuously observes patients –analyzing their movement patterns, actions, and the room environment– to prompt hospital staff and aid in supporting patient safety and care. When paired with telemedicine teams, this creates a modern virtual inpatient command center that supports hospital bedside teams and improves patient care.

“We have a long history of using telemedicine inside the hospital to help patients,” said Derick Ziegler, Baptist Memorial Health Care’s Vice President of Affiliated Integration and West TN Operations. “This experience allowed us to observe the unique aspects of LookDeep’s technology and its compatibility with our telemedicine program.”

“By eliminating hardware costs and only charging hospitals per patient day used, we are able to dramatically drive down the cost of core inpatient video monitoring. This allows us to expand its use to every patient in the hospital and sets the stage for AI to continuously monitor every patient –systemically tackling safety, clinical productivity, and clinical care needs,” said Narinder Singh, CEO and Co-Founder of LookDeep. “We are thrilled to collaborate with Baptist Memorial Health Care, as their deep experience and innovation with telemedicine in urban and rural hospitals is the perfect setting for our AI technology to prove its worth.

“LookDeep’s AI computer vision technology has been developed through research partnerships and thousands of hours of patient video. Its research implications have been presented at the American Thoracic Society Annual Meeting (2022), Machine Learning for Healthcare Annual Conference (2022), Academy of Consultation-Liaison Psychiatry Annual Meeting (2022), and the upcoming American Telemedicine Association Annual Conference in March 2023.

ABOUT BAPTIST MEMORIAL HEALTH CARE

Baptist Memorial Health Care is one of the country’s largest not-for-profit healthcare systems and the largest provider of Medicaid in the region. Baptist offers a full continuum of care to communities throughout the Mid-South and consistently ranks among the top integrated health care networks in the nation. The health care system comprises 22 affiliate hospitals in West Tennessee, North and Central Mississippi and East Arkansas; more than 5,400 affiliated physicians; Baptist Medical Group, a multispecialty physician group with more than 900 providers; home, hospice and psychiatric care; minor medical centers and clinics; a network of surgery, rehabilitation and other outpatient centers; and an education system highlighted by Baptist Health Sciences University (formerly Baptist College of Health Sciences). Baptist employs more than 19,000 people, and in fiscal year 2020 contributed more than $352 million in community benefit and uncompensated care to the communities it serves. For more information, please visit http://www.baptistonline.org or follow us on Facebook.

ABOUT LOOKDEEP

LookDeep is revolutionizing telemedicine by using advanced computer vision and AI technology to help hospitals continuously monitor all patients. Our pioneering zero-cost hardware model and modern, SOC2-certified software dramatically drive down the cost of inpatient video –enabling hospital-wide deployments supported by a virtual command center. AI-powered video monitoring helps tackle critical issues such as patient safety, room conditions, movement and mobility, and patient location and recovery. Through this continuous monitoring, we help doctors and nurses increase the clinical attention on their patients. With LookDeep, hospitals can be present at every moment for every patient.

Share article on social media or email:

Infraway Puts Health and Wellness Market Competitors on Notice with the Release of L1


Infraway, dedicated to the advancement of tech-infused recovery and relief options to increase the overall health and wellness of everyone, today announced the launch of L1, its next-gen, first-of-a-kind IoT-enabled wearable device that incorporates innovative far infrared (FIR) technology with topical heat to provide the next level of self-care options for those that suffer from aches, soreness, and tightness. F.I.R. enables the L1 to penetrate three inches under the skin to provide deeper and more effective therapy to muscle fibers and connective tissue.

“We’re thrilled to share L1 with the world,” stated Max Betkowski, CEO of Infraway. “As a kinesiologist with an engineering background, I understand how muscles and motors work, and knew there were limitations to traditional heating devices that are currently on the market. With L1, users can now gain access to an intricate and discreet device that pairs science and technology to deliver a new way of self-managed care. We believe that our L1 will play a critical role in elevating health and wellness, and ultimately a higher quality of life.”

The Acquisition of Relief Technologies

In the fall of 2022, Infraway acquired Relief Technologies, a San Francisco-based health and wellness company that provided a heating device geared towards alleviating back discomfort. Infraway was introduced to the founders of Relief Technologies in the fall of 2022. After a brief chat with Relief’s founders, it was clear that Infraway and Relief Technologies had a similar approach to helping people proactively take control over their health and wellness and recovery options. Acquisition talks began in September 2022 and the deal was finalized in November 2022. With Relief Technologies’ hardware paired with Infraway’s software and technology components, the acquisition was integral in streamlining the time frame of getting L1 to market.

“We believe that Infraway is a natural home for Relief’s technology, which will supercharge Infraway’s product offering,” stated Jon Thomas, co-founder of Relief Technologies. “We share Infraway’s vision for the future of smart, wearable health and wellness solutions, and we’re excited for the road ahead.”

Relieve, Recover, Refresh

Weighing in at a light 1.5 lbs, the L1 is small and can be worn comfortably over or under clothing, so it doesn’t get in the way of your daily activities and workouts. It fits waists from 25” – 40” with an extension available for 40” – 60” waists. Infraway’s F.I.R. technology is powered by MEtec, one of the innovators in this space. With up to two hours of battery life, it can connect via Bluetooth to the Infraway app for customized control, which allows you to proactively manage your therapy. The 4-way Stretch Lycra + Antimicrobial material allows the product to stretch to adjust the fit as needed. The L1 is one of the most dynamic yet affordable products on the market, available for only $179 per device. To purchase or learn more about Infraway’s L1, visit our product page.

The health and wellness market, valued at $4.9B in 2022, is expected to increase by nearly 20 percent (18.8 percent) by the year 2025. L1’s entrance into this market comes at a time when consumers and a growing number of companies are focused on the value of personalized self-care solutions.

About Infraway

Infraway is a pain management company dedicated to the advancement of recovery and relief options to increase the overall health and wellness of everyone. With its next-generation wearable technology offerings, Infraway combines far infrared (F.I.R.) technology – which provides deeper penetration into muscle fiber and connective tissue – with topical heat to facilitate the body’s natural movement and healing process. Infraway devices are discreet and can be used on the go to provide relief all day long. With its state-of-the-art, IoT-controlled heating devices, users can use bluetooth to manage and gain key insights into their own therapy sessions via the Infraway app, available in the Apple and Android marketplaces. For more information, visit theinfraway.com, and follow us on LinkedIn and Instagram.

Share article on social media or email:



Ohioans for Reproductive Freedom and Ohio Physicians for Reproductive Rights will Conduct Press Conference to Discuss Reproductive Freedom Amendment


Representatives from Ohioans for Reproductive Freedom and Ohio Physicians for Reproductive Rights will conduct a press conference on Tuesday, February 21, to discuss their recently announced partnership and The Right to Reproductive Freedom with Protections for Health and Safety amendment the groups will file with the Ohio Attorney General today.

Who:

  • Dr. Marcela Azevedo, Ohio Physicians for Reproductive Rights
  • Dr. Lauren Beene, Ohio Physicians for Reproductive Rights
  • Professor Jessie Hill, Ohioans for Reproductive Freedom
  • Dr. Sri Thakkilapati, Ohioans for Reproductive Freedom

What: A discussion of the citizen-initiated constitutional amendment that will be filed with the Ohio Attorney General today and an overview of the effort to place the issue on the 2023 General Election ballot.

When: Tuesday, February 21, 2023, 2:00 pm

Where: Registration required:https://aclu.zoom.us/j/89064765019

https://aclu.zoom.us/meeting/register/tZ0vc-qtqD0jHtDgKKEaimkEtwxYcz9coQyR

Note: Following the conclusion of the panel, the virtual press briefing will be opened up for audience Q&A. We ask that non-speakers mute themselves and leave cameras off until the Q&A begins.

For more information about the organizations, visit

ProtectChoiceOhio.com

AbortionAccessOhio.org

###

Share article on social media or email:

Rett Syndrome Research Trust Awards $1.1 Million to Emerald Innovations to Develop Novel Invisible Biosensor for Objective Measures of Rett Symptoms


We are very excited to advance the Emerald device in this rare disease to facilitate better patient management and support the assessment of therapeutics in development.

The Rett Syndrome Research Trust (RSRT) is excited to announce a $1.1 million dollar research award to Dina Katabi, PhD, and her team at Emerald Innovations. The funding will enable Dr. Katabi and Emerald Innovations to continue developing cutting-edge technology to directly and objectively assess symptoms of irregular breathing, sleep disruptions, and movement in individuals with Rett syndrome. The new study builds upon pilot results that demonstrated Emerald’s feasibility to assess Rett syndrome symptoms at home, capturing significant disruptions in sleep and breathing over a four-week period — all without touching the patient.

Emerald technology is invisible, meaning it assesses a patient’s physiology when they are in the vicinity of the device, keeping it in a distinct class from wearable technologies that require constant contact. Emerald also preserves privacy — it does not use cameras or microphones, or capture audio or video. Instead, it uses artificial intelligence (AI) to measure movements, sleep, and vital signs from very low power radio waves in the environment, advancing a new era to collect continuous data at home. It allows families and their loved ones with Rett to go about their daily lives while enabling detailed characterization of various symptoms to generate highly specific representative datasets. Alba Tull, a member of RSRT’s Board of Trustees, investor, and philanthropist generously donated $500,000 to support the upcoming study for Rett syndrome.

Dr. Katabi is the president and co-founder of Emerald Innovations, a spinout from the Massachusetts Institute of Technology (MIT), where Dr. Katabi serves as the inaugural Thuan and Nicole Pham Professor in the Department of Engineering and Computer Science, director of the MIT Center for Wireless Networks and Mobile Computing, and leader of the Networks at MIT Research Group in the Computer Science and Artificial Intelligence Lab. She is a member of the National Academy of Engineering as well as the American Academy for Arts and Sciences, a MacArthur Fellow, and the recipient of various prestigious awards, including the Sloan Research Fellowship and the ACM Computing Prize. In 2015, she presented Emerald to President Obama at White House Demo Day, which focused on breakthroughs in technology.

“We are very excited to advance the Emerald device in this rare disease to facilitate better patient management and support the assessment of therapeutics in development,” said Dr. Katabi. “The breathing and sleep patterns we observed in Rett individuals are quite disrupted, and we are confident that Emerald’s ability to systematically and objectively assess symptoms unobtrusively at home will improve the lives of patients and their families.”

Dr. Katabi’s most recent publications, in Science Translational Medicine and Nature Medicine, demonstrate the power of the technology in Parkinson’s disease. Emerald was able to predict risk of diagnosis, and more sensitively detect prognosis and medication effects than current standards. She hopes insights from Emerald will similarly benefit Rett syndrome.

Members of RSRT’s Biomarker Consortium, consisting of subject matter experts and representatives from biopharmaceutical companies developing genetic medicines for Rett, provided constructive feedback on the study design and will have early access to the data. The Emerald sensor is currently being utilized in drug development for Alzheimer’s disease, Parkinson’s disease, and several immune diseases. Validation of the device in the upcoming Rett study will make it easier to support Rett clinical development efforts as well.

“The Emerald provides direct, objective measures of symptoms captured continuously over days, weeks, months, or longer, generating significantly richer data in shorter timeframes than can be obtained in traditional in-clinic studies,” said Jana von Hehn, PhD, RSRT’s chief scientific officer, who will oversee study operations. “We are excited to continue this important work with Emerald, guided by our Biomarker Consortium and FDA advice, to facilitate more efficient clinical trials and truly effective therapeutics.”

ABOUT THE RETT SYNDROME RESEARCH TRUST

RSRT is a nonprofit organization with a highly personal and urgent mission: achieving a cure for Rett syndrome and related disorders caused by defects in the MECP2 gene. Since its founding in 2008, RSRT has awarded $66 million, more than any other Rett organization in the world, to leading scientists pursuing targeted research on Rett. RSRT funds and spearheads global scientific and clinical activities advancing the most promising curative approaches. To date, every biopharmaceutical company pursuing a cure for Rett syndrome is doing so because they leveraged discoveries and resources incubated with RSRT funding. To learn more, please visit http://www.reverserett.org.

ABOUT EMERALD INNOVATIONS, Inc.

Emerald Innovations, Inc. is a spin-out from MIT that is transforming digital health monitoring from wearables to invisibles. It is based on an artificial intelligence-powered sensor that continuously measures movements, vital signs, sleep, and behavior by analyzing the wireless signals bouncing in the environment. Emerald’s passive technology eliminates the need for patients to wear devices on their body. Emerald is being used by the world’s largest pharma and biotech companies, and leading disease research foundations in clinical trials in all phases, and in a variety of therapeutic areas — neurology, immunology, and rare diseases. For more information, please visit https://www.emeraldinno.com/.

Share article on social media or email:

Bob Kramer Awarded 2023 McKnight’s Career Achievement Award


Bob Kramer Awarded 2023 McKnight’s Career Achievement Award

Bob Kramer Awarded 2023 McKnight’s Career Achievement Award

“There is no one who better exemplifies the commitment, the energy, the insight and the extraordinary persistence needed for devoting one’s life to making life better for elders,” said Dr. Bill Thomas, founder of the Eden Alternative and a Nexus Insights Fellow.

Bob Kramer, one of senior living’s most influential and high-profile thought leaders, has been chosen to receive the 2023 Career Achievement Award as part of the inaugural McKnight’s Pinnacle Awards. The Pinnacle Awards were created to recognize industry veterans who are leading the charge and inspiring change in the fields of senior living, senior care and skilled nursing.

Kramer is the founder of Nexus Insights, a think tank dedicated to advancing the well-being of older adults through innovative models of housing, community and healthcare.

“There is no one who better exemplifies the commitment, the energy, the insight and the extraordinary persistence needed for devoting one’s life to making life better for elders,” said Dr. Bill Thomas, founder of the Eden Alternative and a Nexus Insights Fellow. “If pinnacles got awards, they would be called ‘Bob Kramers’. So much can be said about what Bob has done but — I am most excited about what he has yet to do. His work with Nexus raises the pinnacle to a new level and I see no limit on how high this work can go.”

Bob Kramer has spent over 40 years improving the lives of the aging and those who care for them. In 1991, he co-founded NIC, The National Investment Center for Seniors Housing & Care, a 501(c)(3) organization created to bring private sector investors to the table through education, data and analytics.

“This career award is incredibly fitting for Bob Kramer. He is clearly one of the giants of our field,” said current NIC President and CEO Ray Braun, a former president of Health Care REIT (now Welltower), in an interview with McKnight’s. “We are indebted to Bob for his vision for NIC and his industry leadership. He has impacted thousands. I’m glad to have known him for so many years, and worked beside him, first as an NIC board member and then board chair.”

Kramer has earned the reputation of “agent provocateur” for identifying industries and sometimes-uncomfortable trends that will disrupt the future of seniors housing, aging services, and aging more broadly.

“Bob has been both an innovator and change agent throughout his life: as a state legislator, co-founder and CEO of NIC and, now, as founder and fellow of Nexus Insights,” says Ryan Frederick, Founder & CEO of Here. “He has the rare combination of strategic vision and know-how that has made senior living immeasurably better today and into the future.”

Kramer’s latest self-funded venture, Nexus Insights, comes from his heart and is a way to give back to an industry that has been so good to him. He wants to inspire the next generation of leaders in the seniors housing and aging services space.

“Nexus Insights will help our society to reframe how we think about aging, to address the implicit and explicit ageism prevalent in our culture, and to change what our expectations are for aging, and the very experience of aging,” said Kramer. “In addition and most importantly, Nexus Insights will provide actionable, sustainable and measurable models that can really work.”

The McKnight’s Pinnacle Awards ceremony and dinner will be held March 7, 2023, at the Ivy Room in Chicago.

About Nexus Insights

Nexus Insights is a think tank advancing the well-being of older adults through innovative models of housing, community and healthcare. We are a diverse group of thought leaders and stakeholders in aging and healthcare. Our goal is to spark change by sharing innovation across traditional silos, convening leaders from differing perspectives and bringing positive, life-affirming ideas into the public domain. For more information visit http://www.nexusinsights.net.

Share article on social media or email:

MCI USA Welcomes New Client Optica to Convention Division


News Image

MCI USA’s convention division is pleased to partner with Optica, a global society for professionals in optics and photonics. MCI USA will provide registration and housing services for Optica’s OFC Conference & Exhibition, as well as the CLEO Conference & Exhibition, in 2023 through 2025. With more than 22,000 individual members and 290 corporate members, Optica’s mission is to promote the generation, application and archiving of knowledge in optics and photonics and to disseminate this knowledge worldwide.

“MCI USA is thrilled to be working with Optica,” said Laura Beckum, SVP, Business Development, MCI USA. “This partnership allows us to use our industry-leading registration and housing platform, OneSystem Plus, to provide solutions that will improve the client user experience, as well as the experience of the registrants and those making housing reservations.”

Optica has helped academia and industry collaborate for over 100 years. Since 1916, the organization has championed optics and photonics, uniting and educating scientists, engineers, educators, technicians and business leaders around the world to foster and promote technical and professional development. OFC, the premier event in telecom and data center optics, is the largest global conference and exhibition for optical communications and networking professionals. Optica is a co-sponsor of the Conference on Lasers and Electro-Optics, or CLEO, an international forum for scientific and technical optics, uniting the fields of lasers and opto-electronics by bringing together all aspects of laser technology, from basic research to industry applications.

For over 30 years, MCI USA’s convention division has been providing registration, housing, lead cultivation, and business intelligence solutions to events of all sizes and complexity around the world. MCI’s registration and housing services are powered by OneSystem Plus, the industry’s most complete and customizable registration and housing platform.

ABOUT MCI 

MCI is a global engagement and marketing agency. We design human-centric solutions that unleash the power of people to deliver innovation and growth for our clients. Our offering includes live & virtual events, strategic & digital communications, consulting & community solutions. We help brands, companies, associations and not-for-profits solve their challenges, bringing their people together to shape their tomorrow. MCI is an independently owned company headquartered in Geneva, Switzerland, with a global presence in 60 offices across 31 countries. http://www.wearemci.com 

MCI’s U.S. headquarters is in the Washington, D.C., area with offices in New York, Baltimore, Dallas, and Chicago. http://www.wearemci.com/en-us

Share article on social media or email: